Information Provided By:
Fly News Breaks for July 10, 2019
ICPT
Jul 10, 2019 | 13:45 EDT
Cantor Fitzgerald analyst Alethia Young said she spoke to Intercept's CEO and CFO amid questions from investors about the stock weakness today, which she believes is due to competitor comments around the commercial potential for Ocaliva in PBC and NASH. Management expressed no change in their view for the commercial opportunity for either indication, continue to believe that Ocaliva will be a key therapy for advanced fibrosis patients with NASH and "remain confident in OCA's blockbuster potential," according to Young. She maintains a $191 price target and Overweight rating on Intercept shares.
News For ICPT From the Last 2 Days
There are no results for your query ICPT